Thyrocare promoter Docon sells 9.9% stake in market trades
Thyrocare Technologies promoter Docon Technologies sold 1.57 crore shares (9.9% stake) in market trades on August 13, 2026. Promoter holding drops to 51.02% from 60.92%. Disclosure filed under SEBI Takeover Regulation 29(2).
*this image is generated using AI for illustrative purposes only.
Thyrocare Technologies disclosed that its promoter, Docon Technologies Private Limited, sold a significant block of equity shares in open market trades on August 13, 2026. The transaction marks a substantial reduction in the promoter group’s stake, bringing their total holding below the 60% threshold often monitored by investors for control stability.
Docon sold 1,57,69,696 equity shares during the session. This volume represents approximately 9.90% of the total paid-up equity share capital of Thyrocare. Following the settlement of these trades, Docon continues to be classified as a Promoter and holding company of Thyrocare.
Shareholding Pattern Changes
The sale has materially altered the promoter group's ownership structure. Prior to this transaction, the promoters held 60.92% of the total paid-up equity share capital. Post-transaction, this figure has declined to 51.02%.
| Metric | Value |
|---|---|
| Shares Sold | 1,57,69,696 |
| Stake Sold | 9.90% |
| Pre-Transaction Holding | 60.92% |
| Post-Transaction Holding | 51.02% |
The disclosure was made under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Docon is a wholly owned subsidiary of API Holdings Limited. The company informed both the National Stock Exchange of India Limited and BSE Limited regarding the trade. Settlement of the transaction is being carried out in accordance with applicable laws and regulations.
Madhuri Sudhir Sarangdhar, Company Secretary of Docon Technologies Private Limited, signed the disclosure dated August 13, 2026.
Historical Stock Returns for Thyrocare Technologies
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.67% | -4.06% | +0.28% | +51.02% | +30.84% | +36.31% |
How might the drop in promoter holding below the 60% threshold impact Thyrocare's stock volatility and institutional investor confidence?
What are the likely strategic reasons for Docon Technologies to offload nearly 10% of its stake, and does this signal a broader divestment plan by API Holdings?
Could this significant reduction in promoter stake trigger any mandatory open offer requirements or regulatory scrutiny under SEBI takeover codes?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
